CoChat
Sign Up
Cited by 22Growth Hormone and Insulin-like Growth FactorsHormonal and reproductive studiesPituitary Gland Disorders and Treatments

Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism

Bengtsson, B.-Å.·1998·Growth Hormone & IGF Research
DOI 10.1016/s1096-6374(98)80014-2
Open this paper in CoChat — free account

Abstract

Untreated growth hormone deficiency (GHD) might explain the increased mortality reported in patients with hypopituitarism. These statistics appear to be largely attributable to cardiovascular disease. Differences in fibrinolytic activity regulators, together with dyslipidaemias, abdominal obesity and raised blood pressure in hypopituitarism might explain this increased risk. There is growing evidence that treatment with growth hormone (GH) can rectify most of the cardiovascular abnormalities associated with GHD. The reported improved psychosocial well-being in response to GH treatment may also be important in lowering risk in this group of patients.

Integrity signals

Registry

Crossref · 10.1016/s1096-6374(98)80014-2

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Left untreated, anterior pituitary deficiencies are associated with decreased health and quality of life.

    “Left untreated, anterior pituitary deficiencies are associated with decreased health and quality of life [55-59].”

    From Neuroendocrine Disruptions Following Head Injury (2023) · cites this paper as [58]

  • Undiagnosed and untreated pituitary deficiencies confer increased morbidity and mortality, which can be reversed by appropriate hormone replacement.

    “undiagnosed and untreated deficiencies confer increased morbidity and mortality, which can be reversed by appropriate hormone replacement.”

    From Neuroendocrine Disruptions Following Head Injury (2023) · cites this paper as [58]

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. Erfurth, 1996, Increased cardiovascular mortality in patients with hypopituitarism, Endocrinol Metab, 3, 121
  2. Würster, 1991, Increased prevalence of osteoporosis and arteriosclerosis in patients with conventional substituted pituitary insufficiency: is there a need for growth hormone substitution?, Klin Wochenschr, 69, 769
  3. Johannsson, 1996, Effects of two years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency, Endocrinol Metab, 3, 3
  4. Johannsson, 1996, Effects of two years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency, Endocrinol Metab, 3, 12

Cited by

Sorted by citations

Related

Authors
Bengtsson, B.-Å.
Affiliations
Sahlgrenska University Hospital (SE)
Corresponding author
Bengtsson, B.-Å.
ORCID
Bengtsson, B.-Å.
Venue
Growth Hormone & IGF Research
Publisher
Elsevier BV
Published
1998-02
Volume
8
Pages
77-80
ISSN
1096-6374 (ISSN-L)
DOI
10.1016/s1096-6374(98)80014-2
OpenAlex
W2054052497
Cited by
22
References
33
Citations by year
2025: 1 · 2023: 1 · 2018: 1 · 2017: 2 · 2014: 2 · 2013: 1 · 2012: 2
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Growth Hormone & IGF Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Keywords
growth hormone deficiency, hypopituitarism, premature mortality, cardiovascular disease, fibrinolytic activity, dyslipidemia, abdominal obesity, hypertension, growth hormone therapy, psychosocial well-being
MeSH terms
Cardiovascular Diseases, Fibrinogen, Humans, Hyperlipidemias, Hypertension, Hypopituitarism, Insulin, Insulin Resistance, Obesity, Quality of Life, Recombinant Proteins, Plasminogen Activator Inhibitor 1, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review